The effect of smoking and TP53 mutations on molecular-targeted therapy in lung adenocarcinoma patients

被引：0
|
作者：
Okuda, Katsuhiro [1 ]
Haneda, Hiroshi [1 ]
Yokota, Keisuke [1 ]
Tatematsu, Tsutomu [1 ]
Nakanishi, Ryoichi [1 ]
机构：
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Oncol Immunol & Surg, Nagoya, Aichi, Japan
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
LI-FRAUMENI SYNDROME; CANCER; EGFR; RESISTANCE; JAPAN; GENE; ROS1;
D O I：
10.21037/jtd.2018.09.43
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：S4013 / S4016
页数：4
相关论文
共 50 条
  • [1] Smoking, lung cancers and their TP53 mutations
    Cooper, CS
    MUTAGENESIS, 2002, 17 (04) : 279 - 280
  • [2] Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma
    Qian, Huiwen
    Hou, Chunqi
    Zhang, Yi
    Ji, Shundong
    Zhong, Chongke
    Li, Juan
    Zhang, Qianqian
    Huang, Jianan
    Li, Chong
    Ji, Cheng
    CANCER GENETICS, 2023, 278 : 62 - 70
  • [3] Significance of testing for TP53 gene mutations in lung adenocarcinoma using targeted gene sequencing
    Matsumura, Yuki
    Owada-Ozaki, Yuki
    Suzuki, Hiroyuki
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4147 - S4150
  • [4] Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy
    Saito, Motonobu
    Suzuki, Hiroyuki
    Kono, Koji
    Takenoshita, Seiichi
    Kohno, Takashi
    SURGERY TODAY, 2018, 48 (01) : 1 - 8
  • [5] The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)
    Aisner, Dara L.
    Sholl, Lynette M.
    Berry, Lynne D.
    Rossi, Michael R.
    Chen, Heidi
    Fujimoto, Junya
    Moreira, Andre L.
    Ramalingam, Suresh S.
    Villaruz, Liza C.
    Otterson, Gregory A.
    Haura, Eric
    Politi, Katerina
    Glisson, Bonnie
    Cetnar, Jeremy
    Garon, Edward B.
    Schiller, Joan
    Waqar, Saiama N.
    Sequist, Lecia V.
    Brahmer, Julie
    Shyr, Yu
    Kugler, Kelly
    Wistuba, Ignacio I.
    Johnson, Bruce E.
    Minna, John D.
    Kris, Mark G.
    Bunn, Paul A.
    Kwiatkowski, David J.
    CLINICAL CANCER RESEARCH, 2018, 24 (05) : 1038 - 1047
  • [6] Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy
    Motonobu Saito
    Hiroyuki Suzuki
    Koji Kono
    Seiichi Takenoshita
    Takashi Kohno
    Surgery Today, 2018, 48 : 1 - 8
  • [7] Characterization of TP53 Mutations in Myeloid Neoplasms for Targeted Therapy
    Romero, A. Mindiola
    Loo, E.
    Green, D.
    Houde, B.
    Deharvengt, S.
    Tsongalis, G.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S19 - S19
  • [8] Clinicopathological and Genetic Ancestry Impact of TP53 Mutations in Brazilian Lung Adenocarcinoma Patients
    De Oliveira Cavagna, R.
    Escremim De Paula, F.
    Noriz Berardinelli, G.
    Sant'Anna, D.
    Santana, I.
    Duval Da Silva, V.
    Albino Da Silva, E. C.
    Miziara, J. E.
    Mourao Dias, J.
    De Marchi, P.
    Ferro Leal, L.
    Vieira Reis, R. M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1209 - S1210
  • [9] Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
    He Li
    Lei Yang
    Yuanyuan Wang
    Lingchan Wang
    Gang Chen
    Li Zhang
    Dongchang Wang
    BMC Bioinformatics, 24
  • [10] Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
    Li, He
    Yang, Lei
    Wang, Yuanyuan
    Wang, Lingchan
    Chen, Gang
    Zhang, Li
    Wang, Dongchang
    BMC BIOINFORMATICS, 2023, 24 (01)
12345